TB Alliance’s ZeNix trial in South Africa and Eastern Europe sought to optimize the 6-month treatment regimen with reduced exposure to...
RECENT NEWS IN MDR-TB
This document summarizes the WHO’s review of various diagnostics for TB. Most of it is not new, but important additions are evaluation of...
The Tuberculosis Drug Accelerator, an experiment designed to facilitate collaboration in tuberculosis drug discovery by breaking down...
About RESIST-TB
A movement to promote and conduct research on the treatment and prevention of drug-resistant tuberculosis (DR-TB) and provide access to effective cure and prevention of DR-TB throughout the world.
Recent RESIST-TB Products and Presentations
Upcoming webinars and presentations relating to MDR-TB trials and developments.
Over ten million people will develop tuberculosis (TB) in the world this year; over 500,000 of these will have multidrug-resistant tuberculosis (MDR-TB). Some will receive treatment. However, we know little about the best ways of treating drug-resistant TB (DR-TB) and preventing tuberculosis in people who come in contact with DR-TB patients. TB control efforts require new evidence-based knowledge about optimal treatment regimens, prophylaxis, and regimens involving new TB drugs in order to address the growing health threats of MDR-TB and extensively drug-resistant (XDR) TB.
JOIN THE MOVEMENT!
Get the Latest News & Updates